{"id":48853,"date":"2025-11-24T19:51:24","date_gmt":"2025-11-24T11:51:24","guid":{"rendered":"https:\/\/flcube.com\/?p=48853"},"modified":"2025-11-24T19:51:26","modified_gmt":"2025-11-24T11:51:26","slug":"phrontline-raises-60m-series-pre%e2%80%91a-to-advance-bispecific-adc-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48853","title":{"rendered":"Phrontline Raises $60M Series Pre\u2011A+ to Advance Bispecific ADC Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Phrontline Biopharma<\/strong>, a next\u2011generation antibody\u2011drug conjugate (ADC) company, announced the close of an oversubscribed <strong>USD 60\u202fmillion Pre\u2011A+<\/strong> financing round led by <strong>Lapam Capital<\/strong>, with participation from <strong>Samsung Venture Investment Corporation, Shiyao Guofang Leading Fund, Hankang Capital, Songqing Capital, Jifeng Capital, Sino Biopharmaceutical<\/strong>, and continued support from existing shareholders <strong>Decheng Capital, Med\u2011Fine Capital, and Jianfa Capital<\/strong>. Proceeds will accelerate clinical development and international collaborations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-details\">Financing Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Phrontline Biopharma<\/td><\/tr><tr><td><strong>Amount<\/strong><\/td><td>USD 60\u202fmillion (Series\u202fPre\u2011A+)<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>Lapam Capital<\/td><\/tr><tr><td><strong>New Investors<\/strong><\/td><td>Samsung Venture, Shiyao Guofang Leading Fund, Hankang Capital, Songqing Capital, Jifeng Capital, Sino Biopharmaceutical<\/td><\/tr><tr><td><strong>Existing Investors<\/strong><\/td><td>Decheng Capital, Med\u2011Fine Capital, Jianfa Capital (all increased stakes)<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Clinical advancement, international partnerships, platform expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile\">Company Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> 2022<\/li>\n\n\n\n<li><strong>Focus:<\/strong> <strong>Bispecific antibody\u2011drug conjugates (BsAb\u2011ADCs)<\/strong> and <strong>dual\u2011payload ADCs<\/strong><\/li>\n\n\n\n<li><strong>Platform:<\/strong> Comprehensive ADC technology covering antibody discovery, linker\u2011payload design, site\u2011specific conjugation, and functional evaluation with proprietary IP<\/li>\n\n\n\n<li><strong>Pipeline:<\/strong> Nearly <strong>10 innovative pipelines<\/strong> in precision oncology<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lead-program\">Lead Program<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Target<\/th><th>Indication<\/th><th>Stage<\/th><th>Geography<\/th><\/tr><\/thead><tbody><tr><td><strong>TJ101<\/strong><\/td><td>EGFR\/B7\u2011H3 bispecific ADC<\/td><td>Solid tumors<\/td><td>Clinical enrollment<\/td><td>China &amp; US (simultaneous)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Differentiation:<\/strong> Dual targeting may overcome resistance and improve tumor specificity<\/li>\n\n\n\n<li><strong>Regulatory Path:<\/strong> Simultaneous China\/US filing strategy positions for potential <strong>global partnership<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Global ADC Market<\/strong><\/td><td>$15.4\u202fbillion (2024)<\/td><\/tr><tr><td><strong>Bispecific ADC Pipeline<\/strong><\/td><td>&lt;15% of ADC clinical candidates globally<\/td><\/tr><tr><td><strong>China ADC Financing<\/strong><\/td><td>$2.3\u202fbillion invested in 2024<\/td><\/tr><tr><td><strong>Peak Sales Potential (TJ101)<\/strong><\/td><td>$500\u2011700\u202fmillion (if approved)<\/td><\/tr><tr><td><strong>Competitive Landscape:<\/strong><\/td><td>First\u2011mover advantage in EGFR\/B7\u2011H3 ADC; rivals include <strong>MacroGenics<\/strong> (B7\u2011H3 programs) and <strong>AstraZeneca\/Daiichi<\/strong> (EGFR ADCs)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Valuation:<\/strong> Post\u2011money valuation estimated at <strong>$250\u2011300\u202fmillion<\/strong> , positioning Phrontline for Series\u202fB in <strong>H2\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>International Strategy:<\/strong> Samsung Venture partnership may facilitate <strong>South Korean clinical sites<\/strong> and future global co\u2011development<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phrontline\u2019s clinical development, platform expansion, and market potential. Actual results may differ materially due to risks including clinical trial outcomes, competitive dynamics, and fundraising conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Phrontline Biopharma, a next\u2011generation antibody\u2011drug conjugate (ADC) company, announced the close of an oversubscribed USD&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48854,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[35,20,28,618],"class_list":["post-48853","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-finance","tag-multi-specific-antibodies","tag-phrontline-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Phrontline Raises $60M Series Pre\u2011A+ to Advance Bispecific ADC Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Phrontline Biopharma, a next\u2011generation antibody\u2011drug conjugate (ADC) company, announced the close of an oversubscribed USD 60\u202fmillion Pre\u2011A+ financing round led by Lapam Capital, with participation from Samsung Venture Investment Corporation, Shiyao Guofang Leading Fund, Hankang Capital, Songqing Capital, Jifeng Capital, Sino Biopharmaceutical, and continued support from existing shareholders Decheng Capital, Med\u2011Fine Capital, and Jianfa Capital. Proceeds will accelerate clinical development and international collaborations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48853\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phrontline Raises $60M Series Pre\u2011A+ to Advance Bispecific ADC Pipeline\" \/>\n<meta property=\"og:description\" content=\"Phrontline Biopharma, a next\u2011generation antibody\u2011drug conjugate (ADC) company, announced the close of an oversubscribed USD 60\u202fmillion Pre\u2011A+ financing round led by Lapam Capital, with participation from Samsung Venture Investment Corporation, Shiyao Guofang Leading Fund, Hankang Capital, Songqing Capital, Jifeng Capital, Sino Biopharmaceutical, and continued support from existing shareholders Decheng Capital, Med\u2011Fine Capital, and Jianfa Capital. Proceeds will accelerate clinical development and international collaborations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48853\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-24T11:51:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-24T11:51:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2401-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48853#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48853\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Phrontline Raises $60M Series Pre\u2011A+ to Advance Bispecific ADC Pipeline\",\"datePublished\":\"2025-11-24T11:51:24+00:00\",\"dateModified\":\"2025-11-24T11:51:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48853\"},\"wordCount\":338,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48853#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2401-1.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Finance\",\"Multi-specific antibodies\",\"Phrontline Biopharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48853#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48853\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48853\",\"name\":\"Phrontline Raises $60M Series Pre\u2011A+ to Advance Bispecific ADC Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48853#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48853#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2401-1.webp\",\"datePublished\":\"2025-11-24T11:51:24+00:00\",\"dateModified\":\"2025-11-24T11:51:26+00:00\",\"description\":\"Phrontline Biopharma, a next\u2011generation antibody\u2011drug conjugate (ADC) company, announced the close of an oversubscribed USD 60\u202fmillion Pre\u2011A+ financing round led by Lapam Capital, with participation from Samsung Venture Investment Corporation, Shiyao Guofang Leading Fund, Hankang Capital, Songqing Capital, Jifeng Capital, Sino Biopharmaceutical, and continued support from existing shareholders Decheng Capital, Med\u2011Fine Capital, and Jianfa Capital. Proceeds will accelerate clinical development and international collaborations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48853#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48853\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48853#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2401-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2401-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Phrontline Raises $60M Series Pre\u2011A+ to Advance Bispecific ADC Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48853#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Phrontline Raises $60M Series Pre\u2011A+ to Advance Bispecific ADC Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Phrontline Raises $60M Series Pre\u2011A+ to Advance Bispecific ADC Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Phrontline Biopharma, a next\u2011generation antibody\u2011drug conjugate (ADC) company, announced the close of an oversubscribed USD 60\u202fmillion Pre\u2011A+ financing round led by Lapam Capital, with participation from Samsung Venture Investment Corporation, Shiyao Guofang Leading Fund, Hankang Capital, Songqing Capital, Jifeng Capital, Sino Biopharmaceutical, and continued support from existing shareholders Decheng Capital, Med\u2011Fine Capital, and Jianfa Capital. Proceeds will accelerate clinical development and international collaborations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48853","og_locale":"en_US","og_type":"article","og_title":"Phrontline Raises $60M Series Pre\u2011A+ to Advance Bispecific ADC Pipeline","og_description":"Phrontline Biopharma, a next\u2011generation antibody\u2011drug conjugate (ADC) company, announced the close of an oversubscribed USD 60\u202fmillion Pre\u2011A+ financing round led by Lapam Capital, with participation from Samsung Venture Investment Corporation, Shiyao Guofang Leading Fund, Hankang Capital, Songqing Capital, Jifeng Capital, Sino Biopharmaceutical, and continued support from existing shareholders Decheng Capital, Med\u2011Fine Capital, and Jianfa Capital. Proceeds will accelerate clinical development and international collaborations.","og_url":"https:\/\/flcube.com\/?p=48853","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-24T11:51:24+00:00","article_modified_time":"2025-11-24T11:51:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2401-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48853#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48853"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Phrontline Raises $60M Series Pre\u2011A+ to Advance Bispecific ADC Pipeline","datePublished":"2025-11-24T11:51:24+00:00","dateModified":"2025-11-24T11:51:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48853"},"wordCount":338,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48853#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2401-1.webp","keywords":["ADC \/ XDC","Finance","Multi-specific antibodies","Phrontline Biopharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48853#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48853","url":"https:\/\/flcube.com\/?p=48853","name":"Phrontline Raises $60M Series Pre\u2011A+ to Advance Bispecific ADC Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48853#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48853#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2401-1.webp","datePublished":"2025-11-24T11:51:24+00:00","dateModified":"2025-11-24T11:51:26+00:00","description":"Phrontline Biopharma, a next\u2011generation antibody\u2011drug conjugate (ADC) company, announced the close of an oversubscribed USD 60\u202fmillion Pre\u2011A+ financing round led by Lapam Capital, with participation from Samsung Venture Investment Corporation, Shiyao Guofang Leading Fund, Hankang Capital, Songqing Capital, Jifeng Capital, Sino Biopharmaceutical, and continued support from existing shareholders Decheng Capital, Med\u2011Fine Capital, and Jianfa Capital. Proceeds will accelerate clinical development and international collaborations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48853#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48853"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48853#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2401-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2401-1.webp","width":1080,"height":608,"caption":"Phrontline Raises $60M Series Pre\u2011A+ to Advance Bispecific ADC Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48853#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Phrontline Raises $60M Series Pre\u2011A+ to Advance Bispecific ADC Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2401-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48853"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48853\/revisions"}],"predecessor-version":[{"id":48855,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48853\/revisions\/48855"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48854"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}